Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients

Metabolism: Clinical and Experimental

Volumn 46, Issue 5, 1997, Pages 538-543

  Villa, P ^b   Fulghesu, A M ^b   De Marinis, L ^b   Valle, D ^b   Mancini, A ^b   Pavone, V ^b   Caruso, A ^b   Lanzone, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; NALTREXONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RELEASE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0030973560     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90191-8     Document Type: Article

References (38)

1. Williams T, Berelowitz M, Joffe S, et al: Impaired growth hormone responses to growth hormone-releasing factor in obesity. N Engl J Med 311:1403-1407, 1984
2. Jung R: Endocrinological aspects of obesity, in James WPT (ed): Clinics in Endocrinology and Metabolism, vol 13: Obesity. Philadelphia, PA, Saunders, 1984 pp 597-612
3. De Marinis L, Folli G, D'Amico C, et al: Differential effects of feeding on the ultradian variation of the growth hormone response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa. J Clin Endocrinol Metab 66:598-604, 1988
4. De Marinis L, Mancini A, Folli G, et al: Naloxone inhibition of postprandial growth hormone releasing hormone-induced growth hormone release in obesity. Neuroendocrinology 50:529-532, 1989
5. Scavo D, Facchinetti F, Barletta C, et al: Plasma beta-endorphin in response to oral glucose tolerance test in obese patients. Horm Metab Res 19:204-207, 1987
6. Pasquali R, Cantobelli S, Casimirri F, et al: The role of the opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism 41:763-767, 1992
7. Mason JS, Haber D: Endogenous opiates modulate insulin secretion in flushing non-insulin-dependent diabetics. J Clin Endocrinol Metab 54:693-697, 1982
8. Khawaja XZ, Bailey CJ, Green IC: Central mu, delta and kappa opioid binding sites and brain and pituitary β-endorphin and metenkephalin in genetically obese (ob/ob) and lean mice. Life Sci 44:1097-1105, 1989
9. Goldzieher JW: Polycystic ovarian disease. Fertil Steril 35:371-394, 1981
10. Barbier RL, Smith S, Ryan J: The role of hyperandrogenemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 50:197-210, 1988
11. Dunaif A, Segal KR, Futterweit W, et al: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174, 1989
12. Lanzone A, Villa P, Fulghesu AM, et al: The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: Relationship with obesity and hyperinsulinemia. Hum Reprod 10:1653-1657, 1995
13. Lee EJ, Park KH, Lee BS, et al: Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome. Fertil Steril 660:53-57, 1993
14. Bruni J, Watkins W, Yen SSC: B-endorphin in the human pancreas. J Clin Endocrinol Metab 49:649-651, 1979
15. Givens JR, Wiedeman E, Andersen RM, et al: Beta-endorphin and β-lipotrophin plasma levels in hirsute women: Correlation with body weight. J Clin Endocrinol Metab 50:975-976, 1980
16. Fulghesu AM, Lanzone A, Cucinelli F, et al: Long term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 82:191-196, 1993
17. New MI, Lorenzen F, Lerner AJ, et al: Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab 57:320-326, 1983
18. Bray GA: Classification and evaluation of the obesities. Med Clin North Am 73:161-184, 1989
19. Blum WF, Ranke MB, Kietzmann K, et al: A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin binding protein: Its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70:1292-1298, 1990
20. Juul A, Main K, Blum WF, et al: The ratio between serum insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, -2, -3) decreases with age and is decreased in acromegalic patients. Clin Endocrinol (Oxf) 41:85-93, 1994
21. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
22. Pasquali R, Casimirri F, Venturoli S, et al: Body fat distribution has weight-independent effects on clinical hormonal and metabolic features of women with polycystic ovary syndrome. Metabolism 43:706-713, 1994
23. Barbieri RL, Ryan KJ: Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiology features. Am J Obstet Gynecol 147:90-101, 1983
24. Lanzone A, Fulghesu AM, Andreani CL, et al: Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist. Hum Reprod 5:143-149, 1990
25. Sternbach HA, Annitto W, Pottash ALC, et al: Anorectic effects of naltrexone in man. Lancet 1:388-389, 1982
26. Fulghesu AM, Ciampelli M, Fortini A, et al: Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. Hum Reprod 10:2253-2257, 1995
27. Vettor R, Macor C, Rossi E, et al: Effect of naltrexone treatment on insulin secretion, insulin action and postprandial thermogenesis in obesity. Horm Metab Res 26:188-194, 1994
28. Ghigo E, Procopio M, Boffano GM, et al: Arginine potentiates but does not restore the blunted growth hormone response to growth hormone releasing hormone in obesity. Metabolism 41:560-563, 1992
29. Grossman A, Stubbs WA, Gailland RC, et al: Studies of the opiate control of prolactin, GH, and TSH. Clin Endocrinol (Oxf) 14:381-386, 1981
30. Janik J, Klosterman S, Parman R, et al: Multiple opiate receptor sub-types are involved in the stimulation of growth hormone release by β-endorphin in female rats. Neuroendocrinology 70:69-75, 1990
31. Barbarino A, De Marinis L, Mancini A, et al: Sex-related naloxone influence on growth hormone releasing hormone-induced growth hormone secretion in normal subjects. Metabolism 36:105-109, 1987
32. Isaacs RE, Gardner DG, Baxter JD: Insulin regulation of rat growth hormone gene expression. Endocrinology 120:2022-2028, 1987
33. Dozio N, Scavini M, Beretta A, et al: In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. J Clin Endocrinol Metab 80:1325-1328, 1995
34. Cordido F, Casanueva FF, Vidai JI, et al: Study of insulin-like growth factor 1 in human obesity. Horm Res 36:187-191, 1991
35. Rasmussen MH, Hvidberg A, Juul A, et al: Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor 1 levels in obese subjects. J Clin Endocrinol Metab 80:1407-1415, 1995
36. Rasmussen MH, Frystyk J, Andersen T, et al: The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-I (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 43:315-319, 1994
37. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor-I and its structural homology with proinsulin. J Biol Chem 253:2769-2776, 1978
38. Morris RS, Carmina E, Vrjod MA, et al: Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertil Steril 63:742-746, 1995